VIVACELLE BIO, Inc. is a clinical stage biotechnology company focused on creating products that utilize our patented phospholipid nanoparticle technology to design products that increase the survivability of critically ill patients. Our phospholipid nanoparticles are 7-300mm in diameter and comprised of phospholipids that form micelles and liposomes. Micelles and liposomes of various sizes make up the different formulations that we have invented with a pipeline of ten products. Our research has revealed that particles of different sizes possess different properties such as reversible absorption of nitric oxide without complication that are beneficial in specific conditions of critical illness. Vivacelle Bio, Inc. has two products that have been cleared by the FDA for phase II clinical trials. We recently concluded a very successful phase II clinical trial of VBI-S for septic shock. We are proceeding with phase 3 and will begin our phase 2 trial of VBI-1 for severe blood loss.